ATE324886T1 - Feste arzneizusammensetzung enthaltend 4'-cyano- trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy- 2-methylpropiono- m toluidide und pvp - Google Patents

Feste arzneizusammensetzung enthaltend 4'-cyano- trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy- 2-methylpropiono- m toluidide und pvp

Info

Publication number
ATE324886T1
ATE324886T1 AT02718317T AT02718317T ATE324886T1 AT E324886 T1 ATE324886 T1 AT E324886T1 AT 02718317 T AT02718317 T AT 02718317T AT 02718317 T AT02718317 T AT 02718317T AT E324886 T1 ATE324886 T1 AT E324886T1
Authority
AT
Austria
Prior art keywords
drug
alpha
methylpropiono
fluorophenylsulphonyl
toluidide
Prior art date
Application number
AT02718317T
Other languages
English (en)
Inventor
Julie Kay Cahill
Nicola Frances Bateman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27354679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE324886(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0101171A external-priority patent/SE0101171D0/xx
Priority claimed from SE0102957A external-priority patent/SE0102957D0/xx
Priority claimed from SE0103565A external-priority patent/SE0103565D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE324886T1 publication Critical patent/ATE324886T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02718317T 2001-04-02 2002-03-27 Feste arzneizusammensetzung enthaltend 4'-cyano- trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy- 2-methylpropiono- m toluidide und pvp ATE324886T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0101171A SE0101171D0 (sv) 2001-04-02 2001-04-02 Pharmaceutical formulation
SE0102957A SE0102957D0 (sv) 2001-09-04 2001-09-04 Pharmaceutical formulation
SE0103565A SE0103565D0 (sv) 2001-10-25 2001-10-25 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
ATE324886T1 true ATE324886T1 (de) 2006-06-15

Family

ID=27354679

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02718317T ATE324886T1 (de) 2001-04-02 2002-03-27 Feste arzneizusammensetzung enthaltend 4'-cyano- trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy- 2-methylpropiono- m toluidide und pvp

Country Status (21)

Country Link
US (1) US20040138299A1 (de)
EP (1) EP1381358B1 (de)
JP (1) JP2004525164A (de)
KR (1) KR20030087048A (de)
CN (1) CN1536993A (de)
AT (1) ATE324886T1 (de)
BR (1) BR0208421A (de)
CA (1) CA2443040A1 (de)
CZ (1) CZ20032647A3 (de)
DE (1) DE60211139T2 (de)
EE (1) EE200300476A (de)
ES (1) ES2261655T3 (de)
HU (1) HUP0303454A3 (de)
IL (1) IL157955A0 (de)
IS (1) IS6970A (de)
MX (1) MXPA03008999A (de)
NO (1) NO20034386L (de)
NZ (1) NZ528284A (de)
PL (1) PL365330A1 (de)
SK (1) SK12032003A3 (de)
WO (1) WO2002080902A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK10722003A3 (sk) * 2001-02-27 2004-02-03 Astrazeneca Ab Farmaceutická formulácia obsahujúca bicalutamid v pevnej disperzii s enterickým polymérom a jej použitie
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
CA2589265A1 (en) * 2004-11-29 2006-06-01 Novartis Ag Dosage regimen of an s1p receptor agonist
WO2006090129A2 (en) * 2005-02-23 2006-08-31 Astrazeneca Ab Bicalutamide for delivering increasing steady state plasma levels
US7785629B2 (en) * 2005-06-21 2010-08-31 Helm Ag Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
CN101272769B (zh) * 2005-07-28 2013-04-24 Isp投资有限公司 生物利用度提高的苯醌类化合物
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
US10189957B2 (en) * 2007-01-26 2019-01-29 Isp Investments Llc Formulation process method to produce spray dried products
DK2278960T4 (da) 2008-03-17 2020-01-27 Actelion Pharmaceuticals Ltd Dosisregimen til en selektiv sip1 receptoragonist
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
CN103282346B (zh) 2011-01-13 2014-11-19 比皮艾思药物研发有限公司 用于制备苯基氨基甲酸酯衍生物的方法
EP2797879B1 (de) 2011-12-27 2018-12-26 Bio-Pharm Solutions Co., Ltd. Phenylcarbamatverbindungen zur verwendung bei der linderung oder behandlung von schmerzen und neuropathischen schmerzen
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
US10046151B2 (en) 2013-07-03 2018-08-14 Lts Lohmann Therapie-Systeme, Ag Transdermal therapeutic system with electronic component
WO2015177212A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
US11633367B2 (en) * 2014-05-20 2023-04-25 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
WO2015177209A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
ES2839128T3 (es) 2014-12-05 2021-07-05 Aragon Pharmaceuticals Inc Composiciones anticancerosas
MX381829B (es) 2014-12-05 2025-03-13 Aragon Pharmaceuticals Inc Composiciones anticancerígenas.
RS66323B1 (sr) 2014-12-05 2025-01-31 Aragon Pharmaceuticals Inc Sastavi protiv raka

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0748220A4 (de) * 1994-01-21 1997-09-10 Sepracor Inc Verfahren und zusammensetzungen zur behandlung von androgen-abhängigen krankheiten unter verwenddung von optisch reinem r-(-)casodex
DE60039379D1 (de) * 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia

Also Published As

Publication number Publication date
NZ528284A (en) 2005-04-29
WO2002080902A1 (en) 2002-10-17
CZ20032647A3 (cs) 2004-09-15
US20040138299A1 (en) 2004-07-15
IL157955A0 (en) 2004-03-28
MXPA03008999A (es) 2004-02-12
DE60211139T2 (de) 2007-03-01
CN1536993A (zh) 2004-10-13
IS6970A (is) 2003-09-29
ES2261655T3 (es) 2006-11-16
NO20034386L (no) 2003-11-28
PL365330A1 (en) 2004-12-27
SK12032003A3 (sk) 2004-03-02
EP1381358B1 (de) 2006-05-03
JP2004525164A (ja) 2004-08-19
NO20034386D0 (no) 2003-10-01
HUP0303454A2 (hu) 2004-01-28
DE60211139D1 (de) 2006-06-08
EE200300476A (et) 2003-12-15
HUP0303454A3 (en) 2005-12-28
EP1381358A1 (de) 2004-01-21
BR0208421A (pt) 2004-03-30
KR20030087048A (ko) 2003-11-12
CA2443040A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
ATE324886T1 (de) Feste arzneizusammensetzung enthaltend 4'-cyano- trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy- 2-methylpropiono- m toluidide und pvp
ATE309798T1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
UY27186A1 (es) Formulación farmacéutica
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
DK1471892T3 (da) Transdermalt terapeutisk system til parkinsons sygdom, der inducerer höje rotigotinplasmaniveauer
MXPA03011538A (es) Composicion medicinal que sustancialmente no causaria dano a la mucosa intestinal.
ATE482747T1 (de) Neue amide derivate und deren pharmazeutische verwendungen
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
MXPA05011076A (es) Derivados de quinazolina para el tratamiento de cancer.
DE50203456D1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
ATE292453T1 (de) Antivirale arznei
DE60004797D1 (de) Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure
SE0103424D0 (sv) Pharmaceutical formulation
BR0109747A (pt) Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática
SE0103839D0 (sv) Pharmaceutical formulation & product
PL368686A1 (en) Novel aminobenzoephenones
AU2002223970A1 (en) Kyberdrug as autovaccines with immune-regulating effects
UY26595A1 (es) Formulaciones de entecavir de dosis bajas y uso
ATE454139T1 (de) Arzneimittel mit shikonin als wirkstoff
SE0103838D0 (sv) Pharmaceutical formulation & product
SE0102887D0 (sv) New formulation
ATE284696T1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
EA200101157A1 (ru) 14β-H-СТЕРОЛЫ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ЭТИХ ПРОИЗВОДНЫХ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ, РЕГУЛИРУЮЩИХ МЕЙОЗ
SE0102886D0 (sv) New formulation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties